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Mitochondria have been increasingly recognized as the important players in the aging process.
Most aging-related diseases, particularly, neurodegenerative diseases, have mitochondrial involvement.
A PubMed search for mitochondria and aging lists 704 articles in 2018. This is not surprising as
mitochondria are involved not only in energy production through oxidative phosphorylation but
also play an important role in intracellular homeostasis, calcium balance, and the metabolism and
interconversion of our dietary substrates, fats, proteins, and carbohydrates, in the fed and fasting
states. They have an important role in signaling their metabolic state to the nucleus and to other cells in
response to stress. Mitochondria have their own protein synthetic apparatus and replicate themselves,
pathways readily disrupted in disease and aging. They are constantly involved in fusion and fission,
the balance of which is essential for cell health. These organelles participate in apoptosis, they make
most of the cell’s free radicals, and they are crucially important for innate immunity. Mitochondrial
DNA has an estimated 10-fold greater mutation rate than nuclear DNA and less repair capacity, and this
plays an important role in aging and cancer. Mitochondria are impacted by environmental factors
and toxins, and different mtDNA haplogroups originally adapted to geographically different origins
make an important background contribution to disease. As mitochondria play a critical metabolic role
in all organ systems, they are particularly impacted by disease and contribute to the aging process
itself. The invited review articles in this special supplement cover most of the common diseases of
aging. Enthusiasm for this supplement in Biology was driven by the opportunity to review the current
state of knowledge about the role of mitochondria in the aging process. The international group of
contributing authors includes many of the leaders in their fields.
This special issue starts with the discussion on the role of mitochondria in a number of critical
organ systems; starting with the immune system, the cell danger response and healing, skin aging,
the role of coenzyme Q and vitamin D, mitochondria and the retina, and drug toxicity in the geriatric
population. The focus then moves to specific diseases of aging the role of mitochondria in diabetes,
cancer, cardiovascular disease, and neurodegenerative disorders;amyotrophic lateral sclerosis (ALS),
multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. Finally, an important paper focusing
on muscle and aging points out the important therapeutic role of exercise.
Increasingly the role of mitochondria in innate immunity has been studied but, as noted by
Peter McGuire [1], the importance of mitochondrial dysfunction in aging and immunity is less
discussed. He provides an overview of three main effects of aging on this system, inflammation
with aging, susceptibility to viral infections, and declining T-cell function. He points out the role
of mitochondrial damage associated molecular patterns (mtDAMPs), which when released from
mitochondria as a consequence of stress, apoptosis, or necrosis, trigger caspase-1 activation with the
release of pro-inflammatory cytokines. He discusses the increased susceptibility of older adults to viral
infections, and the role that mitochondria play in innate immune signaling against viruses and the
production of protective type I interferons. Finally, he discusses the hypothesis that T-cell dysfunction
in aging is due to a decline in mitochondrial function.
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Robert Naviaux [2] discusses a holistic new model of incomplete healing and its role in aging.
He explores the role of mitochondria in the healing process and the effects of aging. He points out that
healing involves the cell danger response and that metabolic cross-talk between mitochondria and the
nucleus, between neighboring and distant cells via signaling metabokines regulates the completeness
of healing. He discusses the causes of cellular stress and the role of mitochondria in the cell danger
response, pointing out the critical roles of purinergic and sphingolipid signaling pathways. Finally,
this paper discusses that cellular arrest in the various phases of the cell danger response leads to chronic
inflammatory and pain syndromes, to susceptibility to bacterial and viral infections, to a variety of
aging-related diseases as well as autoimmune disorders, and to neurodegenerative diseases.
Isabella Peixoto de Barcelos and Richard H. Haas [3] review, from a translational perspective,
the data regarding the association of CoQ10 and aging. They discuss the changes in coenzyme Q levels
during the aging process and its putative contribution to aging diseases through a wide variety of
metabolic roles. CoQ10 functions in membranes throughout the cell where antioxidant and signaling
roles predominate. They explore the growing evidence that oxidative stress is a major component
of cellular senescence, a multifactorial process that involves DNA, protein, and lipid damage and
activation of signaling pathways associated with aging. They discuss the state of the evidence that
CoQ10 supplementation may be helpful for diseases of aging and aging itself.
Roisin Stout and Mark Birch-Machin [4] review the increasing evidence that mitochondrial
dysfunction and oxidative stress contribute to skin aging. They discuss the important mitochondrial
role and energy production in cell signaling, wound healing, pigmentation, vasculature homeostasis,
and hair growth, as well as defense against infection. They explore the free radical theory of aging in
the skin and point out that mtDNA deletions are increased in aged UV exposed epidermis. They review
the role of calorie restriction on skin models of aging and the role of mitochondria in the pigmentary
changes of aging. Finally, they discuss the role of mitochondria in photoaging, effects of pollution,
stress-induced skin wrinkle formation, and hair loss and greying.
Sunil J. Wimalawansa [5] explores the role of vitamin D and its metabolites in the aging process.
He discusses newly recognized functions of vitamin D as controllers of systemic inflammation, oxidative
stress, and mitochondrial respiratory function. He reviews the role of the active metabolite 1,25(OH)2D
as a gene regulator, inhibiting NF-κB expression, which is thought to play a role in many aging-related
disorders, including inflammation and cancer. He explores the evidence that the vitamin D modulates
mitochondrial function and functions as a powerful antioxidant. He points out that hypovitaminosis
D increases the incidence and severity of several age-related common diseases and metabolic disorders
that are linked to oxidative stress, including obesity, insulin resistance, type 2 diabetes, hypertension,
pregnancy complications, memory disorders, osteoporosis, autoimmune diseases, certain cancers,
and systemic inflammatory diseases. Finally, the importance of worldwide vitamin D supplementation
is emphasized.
Janis T. Eells [6] reviews the role of mitochondria in one of the body’s most bioenergetic organs,
the retina. The eye is exposed to visible light and has extensive antioxidant protective mechanisms.
Aging retinal pigment epithelial cells have impaired mitochondrial function with increased reactive
oxygen species production. She notes that aging-related mitochondrial dysfunction causes increased
oxidative injury, which, coupled with impaired repair mechanisms, results in retinal dysfunction and
retinal cell loss, leading to visual impairment. Janis T. Eells discusses the most common cause of
age-related blindness in developed countries, that is, age-related macular degeneration. She discusses
the relationship between mitochondrial function and complement factor H, mutations of which
are a putative risk factor for age-related macular degeneration. Finally, she discusses the role of
mitochondrial dysfunction in diabetic retinopathy and glaucoma.
Yvonne Will, Jefry E. Shields and Kendall B. Wallace [7] bring together extensive academic
and pharmaceutical research experience to discuss the role of mitochondria in drug toxicity in the
elderly. This is an under-explored topic despite its great importance. They note that ‘Drug-induced
mitochondrial toxicity has been described for many different drug classes and can lead to liver, muscle,
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kidney, and central nervous system injury and, in rare cases, to death’. They discuss the progressive loss
of mitochondrial function with age with decreased mitophagy as a cellular surveillance system failure.
They point out that drug mitochondrial toxicity has often not been identified in pre-clinical studies
because young healthy animals are used rather than aged animals with more susceptible mitochondria.
For the many drug classes, the particular drugs with most severe mitochondrial toxic effects can be
revealed by in vitro systems where cells are forced to use mitochondrial respiration. Polypharmacy
in the elderly, coupled with access to over the counter drugs, which inhibit mitochondrial function,
compounds the problem of mitochondrial toxicity. A very useful table of commonly used drugs and
their mitochondrial effects has been provided. Finally, the important effects of lifestyle and diet on
susceptibility to mitochondrial toxicity is discussed.
Magdalene K Montgomery [8] provides a valuable review of the role of mitochondria in obesity
and type 2 diabetes. A discussion of the role of mitochondria in diabetic organ damage focuses
on diabetic cardiomyopathy. A review of the role of mitochondria in insulin resistance finds that
while most of the antidiabetic drugs increase mitochondrial biogenesis with an improvement in
insulin efficacy, particularly, those that modulate peroxisome proliferator-activated receptors, there are
mitochondrial toxic effects caused by many antidiabetic drugs. Finally, she explores the beneficial or
detrimental role of intercellular exchange of mitochondria, mitochondrial DNA, and mitochondrial
fragments through the exchange of exosomes and through nanotubes.
Jason Duran, Armando Martinez and Eric Adler [9] discuss cardiovascular manifestations of
mitochondrial disease and the role of mitochondria in myocardial ischemia and diabetic cardiomyopathy.
Cardiomyocytes are among the most energy dependent cells in the body. They review the mitochondrial
changes with aging and the effects on the heart. They then discuss the cardiac and cardiovascular
manifestations of canonical mitochondrial syndromes. In these disorders, hypertrophic and dilated
cardiomyopathies are commonplace, and a variety of cardiac conduction defects can be life-threatening.
A discussion of mitochondrial dysfunction in cardiac ischemia details the role of mitochondrial
dysfunction and oxidative stress in reperfusion injury, which increases the size of myocardial infarction
through necrosis and mitochondrially mediated apoptosis. Finally, the mitochondrial role in diabetic
cardiomyopathy is discussed.
The next article by Nima B. Fakouri, Thomas Lau Hansen, Claus Desler, Sharath Anugula and
Lene Juel Rasmussen [10] addresses the interactions between mitochondria and cancer. The authors
focus their review on genomic instability, dysregulation of cellular energetics, and mitochondrial
function. They note that DNA damage, secondary to oxidative stress produced by reactive oxygen
and nitrogen species, activates the DNA damage response (DDR), which is an energy-dependent
process. They then elegantly discuss how the DDR can both activate and impair mitochondrial function,
the latter through poly (ADP-ribose) polymerase enzyme hyper-activation. They next discuss the
role of mitochondria-nuclear signaling in aging and cancer, along with the role of ROS. Mitochondria
have an epigenetic role, and, in cancer, mtDNA mutations are associated with a poor prognosis—and
they note a correlation between mitochondrial respiration, cytosolic dNTP pools, and chromosomal
instability. In summary, the connection between mitochondria and cancer is complex but, as the
authors note, ‘the hallmarks of cancer include genomic instability, dysregulation of cellular energetics,
and mitochondrial dysfunction, which also are common pathways important for cellular aging’.
Moving on to neurodegenerative diseases, the review, by Veronica Granatiero and
Giovanni Manfredi [11], discusses the role of mitochondrial dysfunction in the devastating disorder
amyotrophic lateral sclerosis (ALS). They note that neurons are very energy dependent, and
mitochondrial transport and turnover is critical for neuronal and axonal health. In both genetic
ALS and 90% of sporadic cases, mitochondrial dysfunction is manifest by changes in fusion, fission,
and transport. These protein ‘motors’ are ATP dependent. They note that in ALS, microtubular
kinesin anterograde mitochondrial transport and dynein retrograde transport are both disrupted. The
ATP/ADP ratio is an important component of the signaling system for mitochondrial transport. The
hypothesis that protein aggregates in ALS bind to and damage mitochondria causing dysfunction
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is discussed. Gene mutations linked to ALS are involved in mitochondrial quality control. The
authors note that a recent study shows that the actin cytoskeleton plays a part in isolating damaged
mitochondria from the rest of the network. Mitophagy is increased, and Parkin levels are decreased, in
animal models and human ALS, suggesting that the decline in Parkin protein is related to mitophagy.
Whether mitochondrial dysfunction in ALS is a cause or an effect remains unclear, but mitochondrial
fusion, fission, and transport have an important role in this disease.
Isabella Peixoto de Barcelos, Regina M. Troxell and Jennifer S. Graves [12] discuss the role of
mitochondria in multiple sclerosis (MS). Decreases in oxidative phosphorylation and mitochondrial
transport have been documented. MS is an inflammatory disorder with acute and chronic
phases, involving both mitochondrial innate immunity and chronic inflammation followed by
neurodegeneration. They note that mitochondrial dysfunction occurs as a consequence of inflammation
and oxidative stress with ROS production. Nucleic acid, protein, and lipid damage ensue. A fall in
ATP production ultimately triggers mitochondrially mediated apoptosis. Mitochondrial stress impairs
oligodendrocyte function. Studies in human cortex confirm increased levels of mtDNA mutations,
mtDNA depletion, and impairment in complex I and III enzyme activity. Mitochondrial changes in
animal models are reviewed. Experimental autoimmune encephalomyelitis, an animal model of MS,
shows mitochondrial swelling and dysfunction with some evidence for antioxidant rescue. The authors
note that some mtDNA diseases due to point mutations, such as Leber’s Hereditary Optic Neuropathy,
can have an MS phenotype, and MS-like demyelinating disease has been reported in a variety of
mitochondrial-nuclear gene defects, including PolG and OPA1. Large population studies have failed to
confirm an increased incidence of mtDNA mutations in the MS population, although the JT haplogroup
does have an increased MS risk. Finally, the authors discuss the role of mitochondrial therapies in MS.
Chun Chen, Doug M. Turnbull and Amy K. Reeve [13] provide a current review of the mitochondrial role
in Parkinson’s disease (PD). Evidence for mitochondrial involvement stretches back 40 years. They discuss
mitochondrial pathways involved in PD and the rapid growth of knowledge resulting from genomic
sequencing of familial cases. Evidence for complex I deficiency in animal models and human disease is
discussed. High levels of mtDNA clonal deletions are found in substantia nigra neurons in normal aging and
PD, with ROS as a likely contributing factor. This aging-related mtDNA pathology in substantia nigra likely
contributes to susceptibility to PD, and alpha-synuclein can increase mitochondrial membrane permeability,
ROS production, and cell death. The authors discuss recent data on cytosolic calcium oscillations with
the import of calcium into mitochondria, which likely plays a role in cell death. Mutations in two genes
VSP35 and CHCHD2, which impair the mitochondrial function, are responsible for autosomal dominant PD.
These and the roles of mutations in PINK1 and Parkin in mitophagy are discussed. Finally, we are treated to
a detailed discussion of mitochondrial turnover and dynamics and the putative role of protein aggregation
in PD. The authors conclude that mitochondrial complex I deficiency plays a key role in PD, and the likely
causes are elegantly discussed.
Ian Weidling and Russell H. Swerdlow [14] review the evidence for a mitochondrial role in
Alzheimer’s disease (AD). Starting with longstanding evidence of brain hypometabolism, they discuss
findings of mitochondrial electron transport enzyme deficiencies and, in particular, cytochrome oxidase
(COX) deficiency in Alzheimer’s brain. Recent studies confirm mitochondrial structural abnormalities
in Alzheimer’s brain, likely the result of a fusion-fission malfunction, which may be related to amyloid
beta accumulation. An interesting reciprocal relationship between mtDNA deletions and aging noted
in AD brain is discussed, and the evidence for increased oxidative injury in AD brain compared
to age-matched controls is reviewed. Cybrids created from AD mtDNA show similar changes to
the brain with COX deficiency. A mitochondrial interaction with Alzheimer’s protein aggregates is
discussed. Mitochondrial toxins can induce the formation of AD-like Tau alterations, and, in mouse
models, mitochondrial dysfunction precedes amyloid plaque accumulation. The authors note that it
is unclear whether mitochondrial changes are the cause or effect of abnormal protein accumulation
in AD. Amyloid beta inhibits COX activity, and Tau accumulation disrupts mitochondrial transport.
ApoE4 overexpression impairs electron transport complexes. The role of mitochondria in clearing
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protein aggregates is reviewed. Finally, the multiple effects of mitochondrial dysfunction and the
Integrated Stress Response (activated in AD) on gene expression are discussed. The authors conclude
that given the multiple lines of evidence of mitochondrial dysfunction in AD—this is a reasonable
therapeutic target.
This special edition on mitochondrial dysfunction in aging concludes with a discussion of treatment.
Sarcopenia is an inevitable consequence of aging. Mats I Nilsson and Mark A Tarnopolsky [15] detail
the role of exercise as a treatment for mitochondrial aging. An overview of mitochondrial evolution
leads on to a discussion of the homeostatic role of mitochondria and their role in defense against the
three main aging changes, oxidative injury, protein aggregation, and inflammation. An integrated
system’s hypothesis of aging is developed with mitochondria playing a central role. The role of
mitochondrial ROS is discussed, and the authors point out that oxidative phosphorylation decline is
an aging phenomenon in all species along with a variety of structural and functional mitochondrial
changes. Age-related protein aggregation and lipofuscin accumulation result in an accumulation of
cellular debris impervious to lysosomal and proteasomal degradation. The mitochondrial role in the
chronic inflammation of aging is explored. The authors then turn to the role of exercise in correcting the
cellular decline of aging. A convincing case is made for the benefit of exercise, slowing aging-related
changes, including reducing intracellular danger signals, rejuvenating mitochondria, assisting with
intracellular garbage clearance, and decreasing aging-related inflammation.
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